Screener
BridgeBio Pharma BBIO Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 94.4%-1.8pp | 95.1%-0.2pp | 95.8%-2.4pp | 95.8%-3.1pp | 96.2%-2.7pp | |
| Operating margin | -69.8%+209pp | -90.5%+457pp | -104.2%+163pp | -172.4%+77.6pp | -278.4%-45.5pp | |
| Net margin | -98.5%+234pp | -125.9%+405pp | -146%+98.9pp | -227.7%-22.8pp | -332.9%-122pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.4× | 0.5×+0.4× | 0.5×+0.2× | 0.4×+0.1× | 0.3×-0.1× | |
| Liquidity | ||||||
| Current ratio | 1.2×-4.0× | 1.5×-3.0× | 2.8×-1.9× | 3.9×+0.7× | 5.2×+0.6× | |
| Per Share | ||||||
| Book value per share | -$12.85-36.9% | -$11.70-34.9% | -$10.89-38.1% | -$10.08-54.4% | -$9.38-61.1% | |
| Valuation | ||||||
| Market capitalization | $13.08B+28.4% | $14.4B+119% | $14.74B+184% | $9.93B+107% | $8.44B+78.1% | |
| Price / sales | 18.3×-10.4× | 24.8×-26.8× | 29.4×+6.0× | 28.1×+6.1× | 35.8×+14.2× |
FAQ
- What are BridgeBio Pharma's profit margins?
- BridgeBio Pharma (BBIO) runs a 94.4% gross margin and a -69.8% operating margin, with a -98.5% net margin.
- Where do BridgeBio Pharma's ratios come from?
- Every ratio is computed from BridgeBio Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
